On March 16, 2026, the long-term follow-up results of the randomized, double-blind, multicenter Phase III PHILA study were published online in The BMJ. The corresponding author is Academician Binghe Xu from the Cancer Hospital, Chinese Academy of Medical Sciences, with Professor Fei Ma (Cancer Hospital, Chinese Academy of Medical Sciences) and Professor Min Yan (Henan Cancer Hospital) as co–first authors. With a median follow-up of 45.5 months, the study demonstrated that first-line treatment with pyrotinib in combination with trastuzumab and docetaxel significantly improved overall survival (OS) in patients with HER2-positive metastatic breast cancer, reducing the risk of death by 26%. These findings establish a dual-targeted regimen that reflects a distinct “China-developed strategy” for first-line treatment in this population.From monoclonal antibodies to small-molecule TKIs: a new era in dual HER2 targeting
HER2-positive breast cancer accounts for approximately 15%–20% of all breast cancers and is characterized by aggressive behavior and poor prognosis. The advent of HER2-targeted therapies has dramatically transformed outcomes for these patients. Since the CLEOPATRA trial demonstrated the survival benefit of pertuzumab combined with trastuzumab and docetaxel, this regimen has been widely adopted as the global standard first-line therapy.
However, pertuzumab primarily targets the HER2 dimerization domain. In contrast, pyrotinib is an irreversible pan-HER tyrosine kinase inhibitor that simultaneously targets HER1, HER2, and HER4, offering broader inhibition of signaling pathways. Previously, pyrotinib combined with capecitabine has shown superior efficacy in second-line treatment and has been approved for clinical use.
Against this backdrop, the PHILA study was designed to evaluate the efficacy and safety of pyrotinib combined with trastuzumab and docetaxel as first-line therapy for HER2-positive metastatic breast cancer. The initial interim analysis, published in The BMJ in 2023, demonstrated a significant improvement in progression-free survival (PFS). The current long-term follow-up further confirms a survival benefit.
Long-term results from PHILA: sustained PFS and significant OS benefit
The PHILA study enrolled 590 patients with HER2-positive metastatic breast cancer across 40 centers in China. Patients were randomized in a 1:1 ratio to receive either pyrotinib (400 mg orally once daily) plus trastuzumab and docetaxel, or placebo plus trastuzumab and docetaxel, administered in 21-day cycles. The primary endpoint was investigator-assessed PFS. Data cutoff was May 30, 2025, with a median follow-up of 45.5 months.
The results showed a sustained and clinically meaningful benefit in PFS. In the pyrotinib group, 56% of patients experienced PFS events compared with 83% in the placebo group. Median PFS was 22.1 months versus 10.5 months, corresponding to a hazard ratio of 0.44 and a 56% reduction in the risk of disease progression or death.
Long-term PFS rates further underscored the durability of benefit. At three, four, and five years, PFS rates in the pyrotinib group were 40%, 32%, and 29%, respectively, compared with 10%, 8%, and 4% in the control group. Subgroup analyses demonstrated consistent benefits regardless of prior trastuzumab exposure or hormone receptor status. Notably, among patients previously treated with trastuzumab in the (neo)adjuvant setting, median PFS reached 62.8 months with pyrotinib versus 10.4 months in the control group, suggesting a potential ability to overcome trastuzumab resistance.
Although median OS was not reached in either group, a significant survival advantage was observed. The risk of death was reduced by 26% (HR 0.74). Three-, four-, and five-year OS rates were 80%, 73%, and 66% in the pyrotinib group, compared with 72%, 63.5%, and 58.5% in the control group. The magnitude of OS benefit is comparable to that observed in the CLEOPATRA trial, highlighting the strong therapeutic potential of this regimen.
Tumor response was also notably improved. The objective response rate was 84% in the pyrotinib group versus 72% in the control group, with a median duration of response of 22.3 months compared with 10.4 months, indicating both deeper and more durable responses.
An additional important finding was the delay in the onset of brain metastases. Among patients who developed brain metastases, the median time to occurrence was 16.6 months in the pyrotinib group compared with 9.1 months in the control group, suggesting potential intracranial activity, likely attributable to the ability of small-molecule TKIs to penetrate the blood–brain barrier.
Safety profile: manageable toxicity without new safety signals
No new safety signals were identified during long-term follow-up. The most common grade ≥3 adverse events in the pyrotinib group were neutropenia (63%), leukopenia (53%), and diarrhea (48%), consistent with the known profiles of docetaxel and pyrotinib.
Importantly, grade 3 diarrhea occurred predominantly during the first treatment cycle, with a median duration of only one day. With appropriate prophylaxis using loperamide and dose adjustments, diarrhea was effectively managed, and no patients discontinued treatment due to this adverse event. After discontinuation of docetaxel, the incidence of diarrhea decreased substantially.
Cardiac safety was reassuring, with no significant difference in the incidence of decreased ejection fraction between groups and no reported cases of heart failure.
Academician Binghe Xu: a “China solution” for first-line HER2-positive MBC
Academician Binghe Xu, corresponding author of the study, commented: “The long-term follow-up results of the PHILA study are highly encouraging. With a median follow-up of 45.5 months, the combination of pyrotinib, trastuzumab, and docetaxel not only provides sustained improvement in progression-free survival but also demonstrates, for the first time, a clear overall survival benefit, with a 26% reduction in mortality and a five-year survival rate of 66%. This magnitude of benefit is comparable to that of the international standard pertuzumab-based regimen. As an oral TKI, pyrotinib also offers potential advantages in intracranial disease control.”
He further noted: “Although diarrhea is relatively common, it can be effectively managed with prophylactic measures and dose adjustments, allowing most patients to complete treatment successfully. After discontinuation of docetaxel, gastrointestinal toxicity decreases significantly, improving quality of life. Based on the PHILA study, this combination represents a new first-line treatment option, particularly for patients with prior trastuzumab exposure or those at risk of brain metastases.”
Conclusion
The PHILA study represents the first Phase III trial to demonstrate that a domestically developed irreversible pan-HER inhibitor, when combined with trastuzumab, can provide long-term survival benefits as first-line therapy for HER2-positive metastatic breast cancer.
This dual-target approach offers an effective and innovative treatment option, particularly for patients previously treated with trastuzumab, and shows promise in overcoming resistance. Its potential activity in preventing and managing brain metastases further enhances its clinical value.
As survival data continue to mature, the pyrotinib-based regimen may reshape the first-line treatment landscape for HER2-positive metastatic breast cancer and establish a globally recognized “China solution” in this field.
Expert profiles
Binghe Xu, MD Academician of the Chinese Academy of Engineering Professor of Oncology, Peking Union Medical College Distinguished Medical Educator
Fei Ma, MD, PhD Chief Physician, Professor, Doctoral Supervisor Director, Department of Medical Oncology National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences
Min Yan, MD Deputy Director, Breast Disease Diagnosis and Treatment Center Henan Cancer Hospital
